Compare ESE & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESE | SRRK |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 6.8B |
| IPO Year | 1994 | 2018 |
| Metric | ESE | SRRK |
|---|---|---|
| Price | $322.13 | $51.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $283.33 | $56.17 |
| AVG Volume (30 Days) | 265.9K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 193.15 | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | ★ $37,000,000.00 | N/A |
| Revenue This Year | $21.42 | N/A |
| Revenue Next Year | $6.99 | $534.24 |
| P/E Ratio | $129.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $174.92 | $27.07 |
| 52 Week High | $362.15 | $58.49 |
| Indicator | ESE | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 46.19 |
| Support Level | $283.70 | $44.08 |
| Resistance Level | $346.20 | $51.55 |
| Average True Range (ATR) | 11.39 | 2.43 |
| MACD | -3.25 | -0.65 |
| Stochastic Oscillator | 22.55 | 7.27 |
ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.